Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea™ RNAP, Progresses Towards GMP Linea™ IVT Production Start
March 18, 2024
Applied DNA Announces Joint Development Agreement to Integrate Linea™ IVT Platform into CDMO Kudo Biotechnology’s mRNA Manufacturing Workflow
December 14, 2023
Applied DNA Extends Application of Linea™ IVT Platform to saRNA (self-amplifying mRNA)
November 16, 2023
APDN Partners with Cornell University College of Veterinary Medicine to Accelerate Development of Veterinary Vaccine Platform Targeting Diseases that Impact High-Value Animals
September 14, 2023
APDN Acquires RNA Polymerase Developer Spindle Biotech, Launches LineaIVT™ Platform to Substantially Improve mRNA Manufacturing and Broaden Market Reach
July 13, 2023
APDN to Establish N. America’s 1st Enzymatic Large-Scale cGMP DNA Manufacturing Capacity in New York
October 24, 2022
LineaRx Publishes Manuscript Demonstrating that a LinearDNA™ Vaccine Candidate was Protective in Virus Challenge Trial in Ferrets
September 30, 2022
APDN and the Cornell University College of Veterinary Medicine Announce Research Collaboration to Accelerate Application of LinearDNA™ Platform for Veterinary Health Applications
September 8, 2022
LinearDNA™ Platform Development Milestone: First Successful Administration of LinearDNA In Vivo via Lipid Nanoparticles (LNP)
August 10, 2022
LineaRx and EvviVax Publish Additional Positive Animal Proof-of-Concept Data Supporting LinearDNA™ Platform as a Unique Approach to Veterinary DNA Vaccine Development
July 25, 2022
LineaRx to Present Data Showcasing Advantages of its Enzymatically Produced LinearDNA as Substitute for Plasmid DNA in IVT mRNA Production at the 2nd Annual mRNA-Based Therapeutics Summit
July 22, 2022
APDN Secures Grant from National Grid Partnered with the New York State MEP to Support Manufacture of COVID-19 Diagnostic Kits and Vaccine Candidates
June 9, 2020
APDN and Takis Biotech Announce the Production of Neutralizing Antibodies Against SARS-CoV-2 After DNA Vaccination in Animals
May 4, 2020
APDN High-Sensitivity and High-Throughput COVID-19 Diagnostic Kit Enters Validation Process in Partnership with Stony Brook University Hospital
April 21, 2020
APDN Ships COVID-19 LinearDNA™ Vaccine Candidates to Italian Development Partner to Begin Preclinical Animal Testing
April 15, 2020
APDN Leverages COVID-19 Vaccine Development and Proprietary Linear DNA Manufacturing Capability to Design a High Sensitivity Diagnostic Kit for Virus Detection
March 19, 2020
APDN Updates on COVID-19 Collaboration with Takis Biotech, 4 Preclinical LinearDNA™ Vaccine Candidates Designed
March 2, 2020
LineaRx and Takis Biotech Collaborate for Development of a Linear DNA Vaccine Candidate Against Wuhan Coronavirus 2019-nCoV
February 7, 2020
LineaRx Signs Agreement with TYME Technologies for Functional ICTC Assay Services in Pancreatic Cancer Trial
November 26, 2019
LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction
September 19, 2019